Get the Stockscreener App
2.6174
1.97%
-0.0526
iBio Inc stock is traded at $2.6174, with a volume of 13,352.
It is down -1.97% in the last 24 hours and up +19.52% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.67
Open:
$2.67
24h Volume:
13,352
Relative Volume:
0.11
Market Cap:
$24.67M
Revenue:
$2.05M
Net Income/Loss:
$-27.28M
P/E Ratio:
-0.4544
EPS:
-5.76
Net Cash Flow:
$-18.89M
1W Performance:
-6.52%
1M Performance:
+19.52%
6M Performance:
+31.53%
1Y Performance:
+817.42%
1-Day Range:
$2.6174
$2.72
1-Week Range:
$2.47
$2.83
52-Week Range:
$0.20
$4.98
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio Inc. stock rises Friday, outperforms market - MarketWatch
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
iBio Inc. stock rises Monday, outperforms market - MarketWatch
iBio Unveils AI-Driven Antibody Discovery Strategy - TipRanks
Plant-Based Vaccines Market Is Booming Worldwide 2024-2031 | - openPR
iBio Inc. stock remains steady Thursday, underperforms market - MarketWatch
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments - GlobeNewswire Inc.
Lead molecule identified under Ibio and Astralbio’s myostatin program for obesity - BioWorld Online
iBio and AstralBio Provide Update on Myostatin Program for Obesity - GlobeNewswire
IBio, Inc. and AstralBio Provide Update on Myostatin Program for Obesity - Marketscreener.com
IBIO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
What is going on with iBio Inc? Sentiment Analysis - US Post News
iBio Inc. stock falls Friday, underperforms market - MarketWatch
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
iBio (NYSE:IBIO) Trading 1.6% Higher - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Biafra: Why We Ended Nnamdi Kanu’s Trial – Lawyer Ejimakor - Tori.ng
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IOVA’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Imac Holdings stock hits 52-week low at $1.2 amid market challenges - Investing.com
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now - MarketBeat
Hands off Nnamdi Kanu’s ethnic persecution – IPOB charges Nigerian govt - Head Topics
Analytical Lens: Exploring ITeos Therapeutics Inc (ITOS)’s Financial Story Through Ratios - The Dwinnex
Itau Unibanco Holding S.A. Buys Shares of 767 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
Ipca Laboratories to Consolidate US Generics Business; Shares Up 1% - Indiainfoline
IPOB Says Wanted South African Returnees Are Responsible For Crystal Meth Trafficking In Southeast Nigeria, Vows To Fish Out Producers, Distributors - SaharaReporters.com
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - The Tech Outlook
iBio Inc. stock outperforms market despite losses on the day - MarketWatch
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update - Defense World
iBio Inc. stock rises Thursday, still underperforms market - MarketWatch
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):